Think Bioscience has raised a $55 million Series A led by investors including Regeneron Ventures, Innovation Endeavors and Janus Henderson. The University of Colorado spinout is crafting small molecules aimed at difficult-to-drug targets. While many so-called “undruggable” startups have focused on cancer, Think Bio is developing a treatment for a genetic disease called Noonan syndrome, which it says impacts around one in 2,500 births and can lead to a wide set of symptoms, including heart probl

Jan. 22, 2026 -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in a clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for the treatment of advanced colorectal cancer and other advanced gastrointestinal tumors. The Phase I/II study (NCT07216560) represents the first-in-human (FIH) study of 7MW4911 in the Unit

Jan. 22, 2026 -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with significant unmet needs, today announced positive interim results from the open-label pharmacokinetic (PK) cohort of its ongoing CLEER-001 clinical trial evaluating HT-001 in cancer patients receiving EGFR inhibitor therapy. In the open-label PK cohort, 100% of evaluable patients achieved clinical response by Week 6, accompanied b

January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today acknowledges the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegrizeprument (VEL-101) for the prevention of organ rejection in patients undergoing liver transplantation. Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal antibody fragment originally discovere

Jan. 22, 2026 -- PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the company's total Series B financing to $77 million, and the dosing of the first patient in a Phase 1 clinical trial evaluating PT0511, the company's pan-KRAS degrader. The Series B extension builds on PAQ's previously announced Series B financing, with participation from existing as

Jan. 21, 2026 -- BPGbio, Inc ., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead candidate, BPM31510, for the treatment of primary oenzyme Q10 (CoQ10) deficiency (PCQD). Primary CoQ10 deficiency is an ultra-rare, life-threatening mitochondrial disorder affecting fewer than one in 100,000 individuals. The condition severely impairs cellular energy product

Mendra, Inc. (“Mendra”), a biopharmaceutical company built to advance promising therapies for rare disease medicines, utilizing artificial intelligence (AI), today announced its launch in conjunction with the closing of an $82 million oversubscribed Series A financing. The round was co-led by OrbiMed, 8VC, and 5AM Ventures with participation from Lux Capital and Wing VC. Mendra aims to modernize the development and commercialization of rare disease therapies to more efficiently reach patients o

January 21, 2026 Athos Therapeutics, Inc. ("Athos"), an AI software and clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, announced today that it has been granted US FDA authorization to commence an international Phase 2 clinical trial of ATH-063 in patients with moderately to severely active, biologic-refractory ulcerative colitis. In addition to the main efficacy and safety assessment goals of

January 21, 2026 -- Rosemont Pharmaceuticals Announces License Agreement with Fidelity Biopharma to Market ONTRALFY™ (tizanidine oral solution) for Treatment of Spasticity in Adults. Product will be available nationwide in February Rosemont Pharmaceuticals has announced a license agreement with Fidelity BioPharma Company to market ONTRALFY™ (tizanidine oral solution 2 mg/5 mL) in the United States. Product will be available nationwide in February. ONTRALFY is the first FDA approved oral solut

NeuraLight, the leader in developing precision brain function measures, and Teitur Trophics ApS, a pioneering biotech company developing first-in-class therapeutics for neurodegenerative diseases, today announced that they have entered into a collaboration granting Teitur Trophics access to NeuraLight’s brain function biomarker platform for use in its upcoming clinical trial of TT-P34 in Parkinson’s disease. NeuraLight’s platform provides precise, actionable measures of brain function. The plat